2024-05-22 19:11:31 ET
Summary
- LifeMD, Inc. shares have been volatile over the past year, pulling back 50% from recent highs, but still having tripled in the past 12 months.
- GLP-1 drugs like Zepbound and Wegovy have helped turbocharge growth in LifeMD's weight management business.
- The company is delivering impressive and consistent sales growth and is projected to be profitable by FY2025.
- An updated analysis around LifeMD is presented in the paragraphs below.
We last revisited LifeMD, Inc. ( LFMD ) in July 2023. The shares of this direct-to-patient telehealth platform have been volatile since then. Recently, they have pulled back some 50% from recent highs, but still have more than tripled over the past year. Where do the shares go from here? An updated analysis follows below....
Read the full article on Seeking Alpha
For further details see:
LifeMD: Moving Towards Profitability